William Tidmore, MD
Rheumatology · Valdosta, GANPI 1073695292
Payments from drug & device makers
Across 155 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$618
- Amgen$322
- UCB, Inc.$296
- Pfizer$283
- Novartis$270
- GSK$181
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,84994%
- Education$1826%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 35 | $618 |
| Amgen(2 entities) | 17 | $322 |
| UCB, Inc. | 20 | $296 |
| Pfizer | 15 | $283 |
| Novartis | 13 | $270 |
| GSK | 9 | $181 |
| Sanofi | 6 | $166 |
| Aurinia Pharma U.S., Inc. | 4 | $109 |
| Radius Health, Inc. | 5 | $107 |
| AstraZeneca | 6 | $102 |
| Johnson & Johnson | 1 | $99 |
| E.r. Squibb & Sons, L.L.C. | 4 | $77 |
| ANI Pharmaceuticals, Inc. | 3 | $70 |
| Genentech USA, Inc. | 3 | $56 |
| Dexcom, Inc. | 2 | $50 |
| Mallinckrodt Hospital Products Inc. | 2 | $45 |
| Novo Nordisk | 2 | $39 |
| Fresenius Kabi USA, LLC | 1 | $23 |
| Averitas Pharma Inc. | 1 | $21 |
| Chiesi USA, Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Ascensia Diabetes Care US Inc. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Ascendis Pharma Endocrinology Inc | 1 | $16 |
| Medtronic | 1 | $14 |
How this compares
$3,031 in reported general payments places this provider in the 35th percentile of 177 rheumatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 222 | $1,696,575 |
| Enbrel SureclickEtanercept | 123 | $942,471 |
| RinvoqUpadacitinib | 132 | $881,279 |
| Orencia ClickjectAbatacept | 98 | $562,114 |
| Enbrel MiniEtanercept | 44 | $330,565 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 39 | $283,724 |
| EnbrelEtanercept | 35 | $257,920 |
| BenlystaBelimumab | 46 | $225,323 |
| Humira(Cf)Adalimumab | 23 | $210,819 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 15 | $157,702 |
| ForteoTeriparatide | 33 | $144,978 |
| Xeljanz XrTofacitinib Citrate | 22 | $124,783 |
| OrenciaAbatacept | 20 | $112,031 |
| Cosentyx Sensoready PenSecukinumab | 11 | $111,741 |
| OtezlaApremilast | 23 | $107,461 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf), Creon | $618 | $1,109,760171 claims |
| AmgenEnbrel, Otezla, Prolia | $322 | $393,31174 claims |
| GSKBenlysta | $181 | $225,32346 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $77 | $112,03120 claims |
| Novo NordiskOzempic | $39 | $76,18980 claims |
| SanofiKevzara | $166 | $69,05416 claims |
| AstraZenecaFarxiga | $102 | $43,84964 claims |
| PfizerEliquis, Lyrica | $283 | $22,30343 claims |
| NovartisEntresto | $270 | $9,63112 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil | $16 | $7,93893 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 177 rheumatology providers in Georgia.
Other rheumatology in Valdosta
- Theresa Lawrence FordLawrenceville$2.9M
- Wambui MachuaAtlanta$1.8M
- Brent FlickingerGainesville$1.6M
- James MossellTifton$1.6M
- Roel QuerubinMarietta$1.5M
- Arezou KhosroshahiAtlanta$1.5M
- Sung LimAtlanta$1.3M
- Gary MyersonAtlanta$1.3M
- Jefrey LiebermanDecatur$761K
- Marta BognarGainesville$719K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.